Learn · regulatory literacy

Why is compounded semaglutide going away?

Because the legal basis for it was always temporary. Pharmacies could compound copies of semaglutide only while the FDA listed it as in shortage. The FDA declared the shortage resolved in February 2025; the permissions wound down by April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. In 2026 the FDA went further, proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list - comments closed July 30, 2026, and the final decision is pending.

Published Aug 21, 2026 (ET) · every claim sourced below

The shortage loophole, precisely

Semaglutide is an FDA-approved drug (Ozempic, Wegovy) - which normally means compounders cannot make what is "essentially a copy" of it. The exception is a declared drug shortage: while the FDA's shortage list included semaglutide, compounded copies were permitted, and an entire industry grew inside that window. The window closed when the FDA declared the shortage resolved in February 2025 - after which mass-compounded copies became an actionable violation again, with only a narrow exception for patient-specific products that are not essentially a copy.

This is a textbook case of enforcement discretion: the underlying rule never changed - what changed was the temporary condition that suspended its enforcement.

What is still open, and what to watch

The still-moving part is the FDA's May 2026 proposal not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list - which would close the outsourcing-facility route permanently, shortage or no shortage. The public comment period closed on July 30, 2026 (extended from June 30), and the FDA's final determination is pending with no announced date. A decision can publish any business day.

The dated, source-linked timelines live on the semaglutide and tirzepatide entries, which update within 24 hours of any official change - and the semaglutide calculator page explains how pre-mixed pens differ from the compounded vials this all concerns.

Current statuses mentioned here

Asked and answered

Is compounded semaglutide legal right now?
Routine compounding of semaglutide copies is no longer permitted - the shortage-based permission ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. A narrow exception remains for patient-specific products that are not essentially a copy of the approved drug.
Does this affect Ozempic or Wegovy?
No. Brand semaglutide is an FDA-approved drug and remains exactly as available as before. The wind-down concerns compounded copies of it, not the approved products.
What is the pending 503B exclusion decision?
In May 2026 the FDA proposed to leave semaglutide, tirzepatide, and liraglutide off the 503B bulks list permanently. Comments closed July 30, 2026. If finalized, outsourcing facilities could not compound them from bulk even in a future shortage. The final decision is pending.

Sources

Keep going

What is FDA enforcement discretion?What is the FDA's 503A bulk substances list?Semaglutide reconstitution calculatorTirzepatide reconstitution calculatorAll learn articlesThe full atlas